KRAS and colorectal carcinoma: For metastatic colorectal cancer (CRC), drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been recommended, but patients with KRAS mutations are unresponsive to them and have no other options.